You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pd-1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
Sep 2, 2023

Colorectal Liver Metastases Trial in Nanjing (Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors)

Recruiting
  • Colorectal Liver Metastases
  • Radiation: High- and Low-dose radiotherapy
  • PD-1 Inhibitors
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Sep 13, 2023

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

Not yet recruiting
  • Esophageal Squamous Carcinoma
  • HER-2 Protein Overexpression
  • (no location specified)
Sep 24, 2023

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Oct 24, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

Active, not recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Jul 4, 2023

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Tumors Trial in Guangzhou (Pemigatinib, PD-1 Inhibitors)

Recruiting
  • Carcinoma
  • +4 more
  • Guangzhou, Guangdong, China
    Lei Zhang
Jun 21, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • iNKT Cells
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jul 24, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Alirocumab and Cemiplimab
  • (no location specified)
Jan 31, 2023

Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

Recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Immunotherapy
  • PD-1 blockade
  • +2 more
  • Beijing, Beijing, China
    Qin li
Mar 8, 2023

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023